|
Press release: Uppsala, March 20, 2019. Senzime AB (publ) today announces that
the Department of Neuroanesthesia at the University Hospital in Uppsala has
signed an agreement to buy TetraGraph systems. The agreement is of a minor value
and initially includes five TetraGraph systems and associated disposable
sensors.
[image]
“In 2018, Senzime has begun the rollout of TetraGraph. The agreement with
Akademiska is strategically important for us because it verifies and validates
the need and our solutions also in the home market. ” Says Pia Renaudin, CEO of
Senzime AB.
"We chose TetraGraph, based on EMG, because it is the only technology that does
not require free access to the patient''s hand. This type of monitoring is
particularly important in neuroradiological intervention when the patients are
anesthetized and receive a continuous infusion of muscle-blocking drugs
throughout the procedure,” says Arne Wessén, senior physician at the Academic
Hospital in Uppsala.
“We have begun an important commercial chapter in the company''s history. At the
same time, we have just started the journey towards achieving our ambition to
become a world leader in patient monitoring, where the patient''s needs is in
focus. Allover the world, surgeons, anesthetists and healthcare professionals
have demonstrated the need to improve how patients are followed up before,
during and after surgery. We can now offer them smart, digital solutions for
high quality follow-up and monitoring ”, comments Pia Renaudin, CEO of Senzime
AB.
For further information, please contact:
Pia Renaudin, CEO of Senzime
AB
Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com
TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it
possible to assess patients'' biochemical and physiological processes before,
during and after surgery. The portfolio of technologies includes bedside systems
that enable automated and continuous monitoring of life-critical substances such
as glucose and lactate in both blood and tissues, as well as systems to monitor
patients’ neuromuscular function perioperatively and in the intensive care
medicine setting. The solutions are designed to ensure maximum patient benefit,
reduce complications associated with surgery and anesthesia, and decrease health
care costs. Senzime operates in growing markets that in Europe and the United
States are valued in excess of SEK 10 billion. The company''s shares are listed
on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528
00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was submitted
for publication through the agency of the contact person set out above, on March
20, 2019 15:30. |